Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) EBITDA Margin (2021 - 2024)

Allogene Therapeutics' EBITDA Margin history spans 4 years, with the latest figure at 295327.27% for Q1 2024.

  • For Q1 2024, EBITDA Margin rose 2459273.0% year-over-year to 295327.27%; the TTM value through Dec 2024 reached 1166927.27%, down 89253589.0%, while the annual FY2024 figure was 1166927.27%, 83188096.0% down from the prior year.
  • EBITDA Margin for Q1 2024 was 295327.27% at Allogene Therapeutics, up from 401533.33% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 2.75% in Q4 2021 and bottomed at 2157800.0% in Q4 2022.
  • The 4-year median for EBITDA Margin is 221876.92% (2022), against an average of 355351.96%.
  • The largest annual shift saw EBITDA Margin crashed -215779725bps in 2022 before it skyrocketed 175626667bps in 2023.
  • A 4-year view of EBITDA Margin shows it stood at 2.75% in 2021, then crashed by -78367508bps to 2157800.0% in 2022, then soared by 81bps to 401533.33% in 2023, then grew by 26bps to 295327.27% in 2024.
  • Per Business Quant, the three most recent readings for ALLO's EBITDA Margin are 295327.27% (Q1 2024), 401533.33% (Q4 2023), and 141504.65% (Q3 2023).